Cardiomyopathy, Hypertrophic: Multimedia

References

1. Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D, Clinical Electrophysiology Service, Department of Medicine, Montreal Heart Institute, University of Montreal, Montreal, et al. Sudden death and hypertrophic cardiomyopathy: a review. Can J Cardiol. 2005; 21(5):441-8 (ISSN: 0828-282X).

2. Colombo MG, Botto N, Vittorini S, Paradossi U, Andreassi MG. Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies. Cardiovasc Ultrasound. Dec 19 2008;6:62. [Medline].

3. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res. Mar 1 2008;77(4):659-66. [Medline].

4. Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. Mar 2009;62(3):226-35. [Medline].

5. Van Driest SL, Ackerman MJ, Ommen SR, Shakur R, Will ML, Nishimura RA, et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. Dec 10 2002;106(24):3085-90. [Medline].

6. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. Mar 15 1994;73(8):577-80. [Medline].

7. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. Aug 15 1995;92(4):785-9. [Medline].

8. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. Jun 2006;92(6):785-91. [Medline].

9. [Guideline] Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. Nov 5 2003;42(9):1687-713. [Medline].

10. DeRose JJ Jr, Banas JS Jr, Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis. May-Jun 1994;36(6):475-84. [Medline].

11. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. Jun 1982;65(7):1388-94. [Medline].

12. Musat D, Sherrid MV. Echocardiography in the treatment of hypertrophic cardiomyopathy. Anadolu Kardiyol Derg. Dec 2006;6 Suppl 2:18-26. [Medline].

13. Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. Mar 2009;62(3):226-35. [Medline].

14. [Guideline] Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm. Jun 2008;5(6):934-55. [Medline].

15. Topilski I; Sherez J; Keren G; Copperman I, Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel. talitop@biu.013.net.il. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am J Cardiol. 2006;97(12):1769-1775.

16. Galve E, Sambola A, Saldaña G, Quispe I, Nieto E, Diaz A, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy. A 10-year follow-up study. Heart. May 28 2009;[Medline].

17. Silva LA, Fernández EA, Martinelli Filho M, Costa R, Siqueira S, Ianni BM, et al. Cardiac pacing in hypertrophic cardiomyopathy: a cohort with 24 years of follow-up. Arq Bras Cardiol. Oct 2008;91(4):250-6, 274-80. [Medline].

18. Hagège AA, Desnos M. New trends in treatment of hypertrophic cardiomyopathy. Arch Cardiovasc Dis. May 2009;102(5):441-7. [Medline].

19. Jassal DS; Neilan TG; Fifer MA; Palacios IF; Lowry PA; Vlahakes GJ; Picard MH; Yoerger DM, Cardiac Ultrasound Laboratory, Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J. 2006; 27(15):1805-10 (ISSN: 0195-668X).

20. Streit S, Walpoth N, Windecker S, Meier B, Hess O. Is alcohol ablation of the septum associated with recurrent tachyarrhythmias?. Swiss Med Wkly. Dec 1 2007;137(47-48):660-8. [Medline].

21. You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. Nov 2007;154(5):899-907. [Medline].

22. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol. Oct 1994;24(4):880-5. [Medline].

23. Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. May 1 2007;115(17):2358-68. [Medline].

24. Counihan PJ, McKenna WJ. Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy. J Clin Pharmacol. May 1989;29(5):436-8. [Medline].

25. Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol. Jan 15 1991;67(2):169-74. [Medline].

26. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. Mar 13 2002;287(10):1308-20. [Medline].

27. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. Jun 2006;92(6):785-91. [Medline].

28. Armstrong AT, Binkley PF, Baker PB, et al. Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol. Sep 1998;32(3):704-10. [Medline].

29. Biagini E; Spirito P; Leone O; Picchio FM; Coccolo F; Ragni L; Lofiego C; Grigioni F; Potena L; Rocchi G; Bacchi-Reggiani L; Boriani G; Prandstraller D; Arbustini E; Branzi A; Rapezzi C, Institute of Cardiology, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol. (ISSN: 0002-9149). 2008;101(3):387-92.

30. Bonne G, Carrier L, Richard P, et al. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res. Sep 21 1998;83(6):580-93. [Medline].

31. Bonow RO. Left ventricular diastolic function in hypertrophic cardiomyopathy. Herz. Feb 1991;16(1):13-21. [Medline].

32. Brandenburg RO. Syncope and sudden death in hypertrophic cardiomyopathy. J Am Coll Cardiol. Apr 1990;15(5):962-4. [Medline].

33. Braunwald E. Hypertrophic cardiomyopathy--continued progress. N Engl J Med. Mar 23 1989;320(12):800-2. [Medline].

34. Braunwald E, Wynne J. The Cardiomyopathies and Myocarditides. In: Heart disease: A textbook of cardiovascular medicine. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005. 2005;1667-1682.

35. Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: an introduction to pathology and pathogenesis. Br Heart J. Dec 1994;72(6 Suppl):S2-3. [Medline].

36. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. Sep 1993;22(3):796-804. [Medline].

37. Elliott PM, Brecker SJ, McKenna WJ. Diastolic dysfunction in hypertrophic cardiomyopathy. Eur Heart J. Aug 1998;19(8):1125-7. [Medline].

38. Fananapazir L, Cannon RO 3rd, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation. Jun 1992;85(6):2149-61. [Medline].

39. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation. Sep 1992;86(3):730-40. [Medline].

40. Fananapazir L, Epstein SE. Hemodynamic and electrophysiologic evaluation of patients with hypertrophic cardiomyopathy surviving cardiac arrest. Am J Cardiol. Feb 1 1991;67(4):280-7. [Medline].

41. Hayashida W, Kumada T, Kohno F, et al. Left ventricular regional relaxation and its nonuniformity in hypertrophic nonobstructive cardiomyopathy. Circulation. Oct 1991;84(4):1496-504. [Medline].

42. Hintringer F, Nesser HJ, Niel J, et al. Pacing in distal left ventricular hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. Sep 1998;21(9):1828-30. [Medline].

43. Kubo T; Gimeno JR; Bahl A; Steffensen U; Steffensen M; Osman E; Thaman R; Mogensen J; Elliott PM; Doi Y; McKenna WJ, Department of Medicine, University College London, London, United Kingdom. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol. 2007; (ISSN: 1558-3597). 2007;49(25):2419-26.

44. Losi MA, Betocchi S, Manganelli F, et al. Pattern of left ventricular filling in hypertrophic cardiomyopathy. Assessment by Doppler echocardiography and radionuclide angiography. Eur Heart J. Aug 1998;19(8):1261-7. [Medline].

45. Louie EK, Edwards LC 3rd. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. Jan-Feb 1994;36(4):275-308. [Medline].

46. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. Sep 15 1998;82(6):774-8. [Medline].

47. Maron BJ. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgment?. J Am Coll Cardiol. Feb 1996;27(2):431-2. [Medline].

48. Maron BJ. Q waves in hypertrophic cardiomyopathy: a reassessment. J Am Coll Cardiol. Aug 1990;16(2):375-6. [Medline].

49. Maron BJ, Cecchi F, McKenna WJ. Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J. Dec 1994;72(6 Suppl):S13-8. [Medline].

50. Maron BJ, Klues HG. Surviving competitive athletics with hypertrophic cardiomyopathy. Am J Cardiol. Jun 1 1994;73(15):1098-104. [Medline].

51. McDonald KM, Maurer B. Permanent pacing as treatment for hypertrophic cardiomyopathy. Am J Cardiol. Jul 1 1991;68(1):108-10. [Medline].

52. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation. Nov 1989;80(5):1489-92. [Medline].

53. Piacenza JM, Kirkorian G, Audra PH, Mellier G. Hypertrophic cardiomyopathy and pregnancy. Eur J Obstet Gynecol Reprod Biol. Sep 1998;80(1):17-23. [Medline].

54. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. May 1990;15(6):1279-85. [Medline].

55. Sanghvi NK; Tracy CM, Department of Medicine, George Washington University Hospital, Washington, DC. nsanghvi@gwu.edu. Sustained ventricular tachycardia in apical hypertrophic cardiomyopathy, midcavitary obstruction, and apical aneurysm. Pacing Clin Electrophysiol. 2007; 30(6):799-803 (ISSN: 0147-8389).

56. Seiler C, Hess OM, Schoenbeck M, et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol. Mar 1 1991;17(3):634-42. [Medline].

57. Shapiro LM. Hypertrophic cardiomyopathy in the elderly. Br Heart J. May 1990;63(5):265-6. [Medline].

58. Shirani J, Maron BJ, Cannon RO 3rd, et al. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol. Aug 15 1993;72(5):434-40. [Medline].

59. Spirito P, Bellone P. Natural history of hypertrophic cardiomyopathy. Br Heart J. Dec 1994;72(6 Suppl):S10-2. [Medline].

60. Spirito P, Lakatos E, Maron BJ. Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. Am J Cardiol. May 1 1992;69(14):1217-22. [Medline].

61. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol. Mar 15 1990;15(4):808-13. [Medline].

62. ten Berg JM, Suttorp MJ, Knaepen PJ, et al. Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation. Oct 1994;90(4):1781-5. [Medline].

63. Watkins H. Multiple disease genes cause hypertrophic cardiomyopathy. Br Heart J. Dec 1994;72(6 Suppl):S4-9. [Medline].

64. Webb JG, Sasson Z, Rakowski H, et al. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J Am Coll Cardiol. Jan 1990;15(1):83-90. [Medline].

65. Wigle ED. Impaired left ventricular relaxation in hypertrophic cardiomyopathy: relation to extent of hypertrophy. J Am Coll Cardiol. Mar 15 1990;15(4):814-5. [Medline].

66. Williams L; Frenneaux M, Department of Cardiovascular Medicine, University of Birmingham, Edgbaston, Birmingham, West Midlands, et al. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace. 2007; 9(9):817-22 (ISSN: 1099-5129).

Further Reading

Keywords

hypertrophic cardiomyopathy, HCM, hypertrophic obstructive cardiomyopathy, idiopathic hypertrophic subaortic stenosis, IHSS, muscular subaortic stenosis, asymmetric septal hypertrophy, ASH, sudden death, sudden cardiac death, SCD, arrhythmogenic sudden death, myocardial hypertrophy, cardiomyopathy

Contributor Information and Disclosures

Author

Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice
Michael E Zevitz, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Association, and Michigan State Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Gary E Sander, MD, PhD, Professor, Department of Internal Medicine, Division of Cardiology, Tulane University Health Sciences Center
Gary E Sander, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Heart Association, American Society of Hypertension, Heart Failure Society of America, Louisiana State Medical Society, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Frank M Sheridan, MD, Cardiology, Providence Everett Medical Center
Frank M Sheridan, MD is a member of the following medical societies: American College of Cardiology, American Heart Association, and Society for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.